Schott E, Paul F, Wuerfel JT, Zipp F, Rudolph B, Wiedenmann B, Baumgart DC. Development of ulcerative colitis in a patient with multiple sclerosis following treatment with interferonβ 1a. World J Gastroenterol 2007; 13(26): 3638-3640 [PMID: 17659718 DOI: 10.3748/wjg.v13.i26.3638]
Corresponding Author of This Article
Dr. Daniel C Baumgart, MD, PhD, Division of Gastroenterology and Hepatology, Department of Medicine, Charité Medical Center-Virchow Hospital, Medical School of the Humboldt-University of Berlin, Augustenburger Platz 1, D-13353 Berlin, Germany. daniel.baumgart@charite.de
Article-Type of This Article
Case Report
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Jul 14, 2007; 13(26): 3638-3640 Published online Jul 14, 2007. doi: 10.3748/wjg.v13.i26.3638
Development of ulcerative colitis in a patient with multiple sclerosis following treatment with interferonβ 1a
Eckart Schott, Friedemann Paul, Jens T Wuerfel, Frauke Zipp, Birgit Rudolph, Bertram Wiedenmann, Daniel C Baumgart
Eckart Schott, Bertram Wiedenmann, Daniel C Baumgart, Department of Medicine, Division of Gastroenterology and Hepatology, Charité Medical School, Humboldt-University of Berlin, Germany
Friedemann Paul, Jens T Wuerfel, Frauke Zipp, Cecilie-Vogt-Clinic for Molecular Neurology, Charité Medical School, Humboldt-University of Berlin, Germany
Birgit Rudolph, Department of Pathology, Charité Medical School, Humboldt-University of Berlin, Germany
Author contributions: All authors contributed equally to the work.
Correspondence to: Dr. Daniel C Baumgart, MD, PhD, Division of Gastroenterology and Hepatology, Department of Medicine, Charité Medical Center-Virchow Hospital, Medical School of the Humboldt-University of Berlin, Augustenburger Platz 1, D-13353 Berlin, Germany. daniel.baumgart@charite.de
Telephone: +49-30-450553277 Fax: +49-30-450553983
Received: January 31, 2007 Revised: February 2, 2007 Accepted: March 8, 2007 Published online: July 14, 2007
Abstract
To alert clinicians to a potential novel adverse drug effect of interferonβ 1a, we herein report a patient with relapsing-remitting multiple sclerosis who developed ulcerative colitis following treatment with interferonβ 1a. Ulcerative colitis persisted despite discontinuation of interferonβ 1a treatment and switching the patient to glatiramer acetate. Tacrolimus (FK506), 6-mercaptopurine, and prednisolone were required to induce remission. Both ulcerative colitis and multiple sclerosis were eventually well controlled using this regimen. Our report underscores that caution should be exercised when prescribing immunostimulatory agents in patients with inflammatory bowel disease (IBD) and challenges current efforts to stimulate innate immunity as a novel therapeutic concept for IBD.
